VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.59%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-9.55%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.21M |
| 2 |
Netflix
NFLX
|
$1.05M |
| 3 |
Meta Platforms (Facebook)
META
|
$1.04M |
| 4 |
Adobe
ADBE
|
$995K |
| 5 |
Applied Materials
AMAT
|
$977K |
Top Sells
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
$1.01M |
| 2 |
Progressive
PGR
|
$999K |
| 3 |
Stryker
SYK
|
$984K |
| 4 |
Republic Services
RSG
|
$973K |
| 5 |
Linde
LIN
|
$966K |
Sector Composition
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
New Mountain Finance
NMFC
$1.13B
| $331K | 0.2% |
26,569
-3,696
| -12% | -$46K |
|
177
Oaktree Specialty Lending
OCSL
$1.23B
| $330K | 0.2% |
16,969
+10,619
| +167% | +$206K |
|
178
Alnylam Pharmaceuticals
ALNY
$59.2B
| $329K | 0.19% |
1,731
+414
| +31% | +$78.6K |
|
179
Biogen
BIIB
$20.6B
| $326K | 0.19% |
1,145
+81
| +8% | +$23.1K |
|
180
ADMA Biologics
ADMA
$4.03B
| $326K | 0.19% |
88,335
+4,410
| +5% | +$16.3K |
|
181
PTC Therapeutics
PTCT
$4.55B
| $325K | 0.19% |
7,989
+205
| +3% | +$8.34K |
|
182
Amicus Therapeutics
FOLD
$2.46B
| $325K | 0.19% |
25,836
+1,097
| +4% | +$13.8K |
|
|
PNNT
183
Pennant Park Investment Corp
PNNT
$471M
| $324K | 0.19% |
54,975
+36,832
| +203% | +$217K |
|
|
TSVT
184
DELISTED
2seventy bio
TSVT
| $323K | 0.19% |
31,965
+6,923
| +28% | +$70.1K |
|
|
PHD
185
Pioneer Floating Rate Fund
PHD
$123M
| $321K | 0.19% |
36,927
-802
| -2% | -$6.96K |
|
186
Rhythm Pharmaceuticals
RYTM
$6.78B
| $320K | 0.19% |
19,414
+9,010
| +87% | +$149K |
|
187
Ligand Pharmaceuticals
LGND
$3.25B
| $318K | 0.19% |
4,405
-399
| -8% | -$28.8K |
|
188
Ultragenyx Pharmaceutical
RARE
$3.07B
| $316K | 0.19% |
6,860
+83
| +1% | +$3.83K |
|
|
NSL
189
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $316K | 0.19% |
69,073
-5,485
| -7% | -$25.1K |
|
|
ICPT
190
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $316K | 0.19% |
28,540
+7,922
| +38% | +$87.6K |
|
191
BioMarin Pharmaceuticals
BMRN
$11.1B
| $316K | 0.19% |
3,640
+801
| +28% | +$69.4K |
|
192
Lexicon Pharmaceuticals
LXRX
$396M
| $315K | 0.19% |
+137,450
| New | +$315K |
|
193
Mirum Pharmaceuticals
MIRM
$3.82B
| $314K | 0.19% |
12,129
-4,960
| -29% | -$128K |
|
194
Sixth Street Specialty
TSLX
$2.32B
| $313K | 0.19% |
16,728
-11,461
| -41% | -$214K |
|
195
Travere Therapeutics
TVTX
$1.93B
| $312K | 0.18% |
20,309
+3,635
| +22% | +$55.8K |
|
|
BTX
196
BlackRock Technology and Private Equity Term Trust
BTX
$819M
| $312K | 0.18% |
39,724
-6,373
| -14% | -$50K |
|
197
Petrobras
PBR
$78.7B
| $311K | 0.18% |
22,514
-6,071
| -21% | -$84K |
|
|
JRO
198
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
| $311K | 0.18% |
39,840
-1,278
| -3% | -$9.97K |
|
199
Copel
ELP
$6.77B
| $311K | 0.18% |
45,098
-6,802
| -13% | -$46.9K |
|
200
Enanta Pharmaceuticals
ENTA
$189M
| $309K | 0.18% |
14,438
+7,514
| +109% | +$161K |
|